Life Cycle Management Strategies More Crucial than Ever for Pharmaceutical Success

With shrinking Research and Development (R&D) pipelines and mounting costs involved in drug development, it is becoming increasingly important for pharmaceutical companies to implement suitable Life Cycle Management (LCM) strategies in order to maximize revenues and the lifespan of their portfolios, says business intelligence provider GBI Research.

The company’s latest CBR Pharma report, Life Cycle Management Strategies – Optimizing Revenues & Defending Generic Competition, states that there are three fundamental categories of LCM strategies, namely developmental, commercial, and regulatory/legal strategies, all of which play a key role in boosting the profitability of pharmaceutical products.

Priyatham Salimadugu, Analyst for GBI Research, says successful LCM planning commences early in the life cycle of a drug, ideally during the R&D phase, and that multiple factors, such as timing, disease characteristics and market environment, should be considered when choosing an LCM strategy.

Salimadugu comments “The key to good LCM is not to manage a single product in isolation, but to think in terms of optimizing sales of the company’s entire portfolio, both marketed and R&D, through planning and learning across the organization. However, the changing industry and regulatory environment is impacting the effectiveness of LCM strategies themselves. As such, LCM strategy selection and implementation needs to be a dynamic and adaptive process, and having access to up-to-date market intelligence is a vital factor.”

GBI Research’s report also states that while developmental strategies are implemented to significantly increase revenue during the period of market exclusivity, commercial strategies work to expand a product’s uptake and value.

Salimadugu continues “Developmental LCM strategies focus on increasing the number of patients eligible to receive a drug, such as by expanding its usage for different indications or targeting rare diseases. These strategies also focus on maximizing patient uptake, by offering more convenient methods of administration, improving dosing frequencies, or reducing side effects. Commercial strategies include switching from prescribed to over-the-counter drugs, geographical expansion, and utilizing price flexibility. In this last case, timing and competitive intelligence are crucial to the success of strategic pricing, as altering the price too early or too late may mitigate any benefit.”

This report provides insight into the various stages of pharmaceutical product Life Cycle Management (LCM), including developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of LCM strategies, and keys to their successful implementation.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@gbiresearch.com. Follow us online for the latest industry updates:

Facebook | LinkedIn | Twitter.

​